Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : China partner expects to be able to make 400 mln COVID-19 vaccine doses a year

02/02/2021 | 03:36am EDT

BEIJING, Feb 2 (Reuters) - China's Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca's COVID-19 vaccine per year, doubling a capacity target promised in 2020.

"Kangtai is actively pushing forward procedures for the vaccine's clinical trial and registration in China, and has completed a manufacturing plant and started trial production," the Shenzhen-based firm said in a press release.

The firm obtained rights to supply the AZD1222 vaccine, developed by the Anglo-Swedish drugmaker and Oxford University, in mainland China last year in return for having capacity to produce at least 200 million doses by the end of 2021.

The vaccine might be approved for use in China by mid-2021 after gathering safety data from Phase I and II trials in China and efficacy data from late-stage trials overseas, Leon Wang, head of AstraZeneca's China operation, said in November. (Reporting by Roxanne Liu and Ryan Woo. Editing by Mark Potter)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.07% 8617 Delayed Quote.18.92%
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. -4.03% 108.11 End-of-day quote.-38.05%
All news about ASTRAZENECA PLC
09:45aASTRAZENECA : Anger, confusion spread over UK's new COVID travel rules
AQ
07:20aPFIZER : COVID-19 Vaccine Elicits Strong Immune Response As Second Dose, Thailand Study Sa..
MT
04:32aSINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
RE
04:27aIndia's Serum Institute to invest $68 mln in UK vaccine maker Oxford Biomedica
RE
04:03aASTRAZENECA : MEDIA-UK govt approves Covishield as qualified vaccine for travel - Mint
RE
02:25aOXFORD BIOMEDICA : Swings to H1 Profit on Revenue from COVID-19 Vaccine Manufacturing
MT
01:57aASTRAZENECA : India likely to allow smaller gap between AstraZeneca COVID vaccine doses so..
RE
09/21Shangula Rages Against West's Vaccine Nationalism
AQ
09/21ASTRAZENECA : India calls new UK COVID-19 vaccine rules 'discriminatory'
AQ
09/21ASTRAZENECA : Investment will transform development and commercialisation of new medicines..
PU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 24,1x
Yield 2021 3,27%
Capitalization 133 B 182 B -
EV / Sales 2021 4,46x
EV / Sales 2022 3,59x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 86,17 $
Average target price 136,24 $
Spread / Average Target 58,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.92%184 103
JOHNSON & JOHNSON4.54%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY36.32%208 668